Impact of Big Pharma organizational structure on R&D productivity:
Saved in:
| Format: | Book |
|---|---|
| Language: | English |
| Published: |
Burgdorf
HERZ, Health-Economics-Research-Zentrum
2009
|
| Series: | Schriften zur Gesundheitsökonomie
17 |
| Subjects: | |
| Online Access: | Inhaltsverzeichnis |
| Physical Description: | X, 143 S. graph. Darst. |
| ISBN: | 9783936863161 |
Staff View
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV035782556 | ||
| 003 | DE-604 | ||
| 005 | 20100112 | ||
| 007 | t | ||
| 008 | 091021s2009 d||| |||| 00||| eng d | ||
| 020 | |a 9783936863161 |9 978-3-936863-16-1 | ||
| 035 | |a (OCoLC)501327413 | ||
| 035 | |a (DE-599)BVBBV035782556 | ||
| 040 | |a DE-604 |b ger |e rakwb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-N2 |a DE-12 |a DE-29 | ||
| 082 | 0 | |a 658.57 |2 22/ger | |
| 084 | |a QR 525 |0 (DE-625)142044: |2 rvk | ||
| 245 | 1 | 0 | |a Impact of Big Pharma organizational structure on R&D productivity |c Sebastian Held ... |
| 246 | 1 | |a Impact of Big Pharma organizational structure on Research and Development productivity | |
| 264 | 1 | |a Burgdorf |b HERZ, Health-Economics-Research-Zentrum |c 2009 | |
| 300 | |a X, 143 S. |b graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Schriften zur Gesundheitsökonomie |v 17 | |
| 650 | 7 | |a Betriebliche Forschung |2 stw | |
| 650 | 7 | |a Großindustrie |2 stw | |
| 650 | 7 | |a Innovation |2 stw | |
| 650 | 7 | |a Organisationsstruktur |2 stw | |
| 650 | 7 | |a Pharmazeutische Forschung |2 stw | |
| 650 | 7 | |a Produktivität |2 stw | |
| 650 | 7 | |a Welt |2 stw | |
| 650 | 0 | 7 | |a Pharmazeutische Industrie |0 (DE-588)4045696-1 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Forschung und Entwicklung |0 (DE-588)4017897-3 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Organisation |0 (DE-588)4043774-7 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Großbetrieb |0 (DE-588)4022149-0 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Pharmazeutische Industrie |0 (DE-588)4045696-1 |D s |
| 689 | 0 | 1 | |a Großbetrieb |0 (DE-588)4022149-0 |D s |
| 689 | 0 | 2 | |a Organisation |0 (DE-588)4043774-7 |D s |
| 689 | 0 | 3 | |a Forschung und Entwicklung |0 (DE-588)4017897-3 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Held, Sebastian |e Sonstige |4 oth | |
| 830 | 0 | |a Schriften zur Gesundheitsökonomie |v 17 |w (DE-604)BV017303654 |9 17 | |
| 856 | 4 | 2 | |m HBZ Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=018642044&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-018642044 | ||
Record in the Search Index
| _version_ | 1804140718669692928 |
|---|---|
| adam_text | Titel: Impact of Big Pharma organizational structure on R D productivity
Autor: Held, Sebastian
Jahr: 2009
Table of content V
Table of content
Table of content.........................................................................................................................V
List of figures...........................................................................................................................VI
List of tables............................................................................................................................VII
Abbreviations and acronyms...............................................................................................VIII
1. Introduction.........................................................................................................................1
2. Definition and explanation of key terms...........................................................................9
2.1. What is Big Pharma?....................................................................................................9
2.2. How to define R D....................................................................................................15
2.2.1. R D in general...............................................................................................15
2.2.2. Specific pharmaceutical R D........................................................................18
2.3. Regulatory authorities.................................................................................................26
2.4. Dimensions of innovation....................................:.: ....................................................31
2.4.1. Innovation in general......................................................................................32
2.4.2. Innovation in the pharmaceutical sector.........................................................36
2.5. Metrics to assess innovation potential........................................................................40
3. Common organizational settings for companies.............................................................47
3.1 Introduction taking history as reference.....................................................................47
3.2. Functional structure....................................................................................................51
3.3. Divisional structures...................................................................................................53
3.4. Matrix structure...........................................................................................................58
3.5. R D Organization in the international background...................................................61
3.5.1. Geographic concentration...............................................................................66
3.5.2. Geographic dispersion....................................................................................67
3.5.3. Empirical findings..........................................................................................70
4. Presentation and evaluation of the Big Pharma companies..........................................73
4.1. Introduction.................................................................................................................73
4.2. Pfizer, GlaxoSmithKline.............................................................................................78
4.3. Novartis, Sanofi-Aventis.............................................................................................83
4.4. Johnson Johnson, AstraZeneca...............................................................................89
4.5. Merck Co., Roche...................................................................................................95
4.6. Evaluation.................................................................................................................100
4.7. Look over industry border........................................................................................109
4.7.1. Toyota...........................................................................................................109
4.7.2. Microsoft......................................................................................................112
5. Conclusion........................................................................................................................115
6. References........................................................................................................................121
7. Annex................................................................................................................................133
7.1. Annex A - Exchange rates........................................................................................133
7.2. Annex B Company profiles...................................................................................134
7.3. Annex C - Detailed scorecard calculation.................................................................142
VI
List of figures
Fig. 1.1. Development of the pharmaceutical market........................................4
Fig. 1.2. R D expenditure and performance of the pharmaceutical industry... 5
Fig. 2.1. Branches globalization level matrix..................................................13
Fig. 2.2. Model of a company s business system............................................16
Fig. 2.3. Stylistic R D process in the pharmaceutical industry......................20
Fig. 2.4. Health expenditure per capita (in US$) in the world.........................27
Fig. 2.5. The range of R D-Management and Innovation-Management.......31
Fig. 2.6. Frequency of tracked innovation components...................................41
Fig. 3.1. A possible functional structure of a pharmaceutical company..........51
Fig. 3.2. A possible product structure of a pharmaceutical company..............54
Fig. 3.3. A possible market structure of a pharmaceutical company...............55
Fig. 3.4. A possible geographic structure of a pharmaceutical company........56
Fig. 3.5. A possible matrix structure of a pharmaceutical company...............59
Fig. 3.6. Ideal spectrum of strategies of multinational companies..................62
Fig. 3.7. General view of different international R D configurations...........65
Fig. 4.1. Contribution of the pharmaceutical business segment to total
company sales....................................................................................76
Fig. 4.2. Development of foreign exchange currencies towards the US
dollar.................................................... 77
Fig. 4.3. Directors board of Sanofi-Aventis.....................................................88
Fig. 4.4. Five-year development of pharmaceutical sales in Big Pharma.....101
Fig. 4.5. Five-year observation of Big Parma s R D sales ratio..................102
Fig. 4.6. Average R D input and innovation in Big Pharma........................107
Fig. 4.7. Average R D sales ratio and innovation in Big Pharma................108
List of tables_______________________________________________________________VII
List of tables
Tab. 2.1. Largest pharmaceutical companies in the world in 2006..................10
Tab. 2.2. The R D expenses of the top 15 pharmaceutical companies...........24
Tab. 2.3. Aggregated innovation spending by industry....................................25
Tab. 2.4. Pharmaceutical expenditure and health expectancy in 2005.............26
Tab. 4.1. Pfizer at a glance................................................................................80
Tab. 4.2. GSK at a glance..................................................................................82
Tab. 4.3. Novartis at a glance............................................................................86
Tab. 4.4. Sanofi-Aventis at a glance.................................................................89
Tab. 4.5. J J at a glance...................................................................................91
Tab. 4.6. AstraZeneca at a glance.....................................................................94
Tab. 4.7. Merck at a glance...............................................................................97
Tab. 4.8. Roche at a glance.............................................................................100
Tab. 4.9. Company evaluation value table (I).................................................104
Tab. 4.10. Company evaluation value table (II)................................................105
Tab. 4.11. Results of the balanced scorecard evaluation..................................106
Tab. 4.12. Toyota: Company profile.................................................................111
Tab. 4.13. Microsoft: Company profile.............................................................114
Tab. 5.1. Extract of the most often named therapeutic areas..........................119
Tab. 7.1. Used exchange rates in this work.....................................................133
Tab. 7.2. Pfizer: Company profile...................................................................134
Tab. 7.3. GSK: Company profile....................................................................135
Tab. 7.4. Novartis: Company profile...............................................................136
Tab. 7.5. Sanofi-Aventis: Company profile....................................................137
Tab. 7.6. J J: Company profile......................................................................138
Tab. 7.7. AstraZeneca: Company profile........................................................139
Tab. 7.8. Merck: Company profile..................................................................140
Tab. 7.9. Roche: Company profile..................................................................141
Tab. 7.10. Breakdown of the scorecard calculation - Derivation of the
portfolio parameter..........................................................................142
Tab. 7.11. Breakdown of the scorecard calculation - Total calculation...........143
|
| any_adam_object | 1 |
| building | Verbundindex |
| bvnumber | BV035782556 |
| classification_rvk | QR 525 |
| ctrlnum | (OCoLC)501327413 (DE-599)BVBBV035782556 |
| dewey-full | 658.57 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 658 - General management |
| dewey-raw | 658.57 |
| dewey-search | 658.57 |
| dewey-sort | 3658.57 |
| dewey-tens | 650 - Management and auxiliary services |
| discipline | Wirtschaftswissenschaften |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02137nam a2200517 cb4500</leader><controlfield tag="001">BV035782556</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20100112 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">091021s2009 d||| |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783936863161</subfield><subfield code="9">978-3-936863-16-1</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)501327413</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV035782556</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-N2</subfield><subfield code="a">DE-12</subfield><subfield code="a">DE-29</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">658.57</subfield><subfield code="2">22/ger</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">QR 525</subfield><subfield code="0">(DE-625)142044:</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Impact of Big Pharma organizational structure on R&D productivity</subfield><subfield code="c">Sebastian Held ...</subfield></datafield><datafield tag="246" ind1="1" ind2=" "><subfield code="a">Impact of Big Pharma organizational structure on Research and Development productivity</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Burgdorf</subfield><subfield code="b">HERZ, Health-Economics-Research-Zentrum</subfield><subfield code="c">2009</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">X, 143 S.</subfield><subfield code="b">graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Schriften zur Gesundheitsökonomie</subfield><subfield code="v">17</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Betriebliche Forschung</subfield><subfield code="2">stw</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Großindustrie</subfield><subfield code="2">stw</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Innovation</subfield><subfield code="2">stw</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Organisationsstruktur</subfield><subfield code="2">stw</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pharmazeutische Forschung</subfield><subfield code="2">stw</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Produktivität</subfield><subfield code="2">stw</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Welt</subfield><subfield code="2">stw</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Pharmazeutische Industrie</subfield><subfield code="0">(DE-588)4045696-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Forschung und Entwicklung</subfield><subfield code="0">(DE-588)4017897-3</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Organisation</subfield><subfield code="0">(DE-588)4043774-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Großbetrieb</subfield><subfield code="0">(DE-588)4022149-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Pharmazeutische Industrie</subfield><subfield code="0">(DE-588)4045696-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Großbetrieb</subfield><subfield code="0">(DE-588)4022149-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Organisation</subfield><subfield code="0">(DE-588)4043774-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="3"><subfield code="a">Forschung und Entwicklung</subfield><subfield code="0">(DE-588)4017897-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Held, Sebastian</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Schriften zur Gesundheitsökonomie</subfield><subfield code="v">17</subfield><subfield code="w">(DE-604)BV017303654</subfield><subfield code="9">17</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">HBZ Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=018642044&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-018642044</subfield></datafield></record></collection> |
| id | DE-604.BV035782556 |
| illustrated | Illustrated |
| indexdate | 2024-07-09T22:04:26Z |
| institution | BVB |
| isbn | 9783936863161 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-018642044 |
| oclc_num | 501327413 |
| open_access_boolean | |
| owner | DE-N2 DE-12 DE-29 |
| owner_facet | DE-N2 DE-12 DE-29 |
| physical | X, 143 S. graph. Darst. |
| publishDate | 2009 |
| publishDateSearch | 2009 |
| publishDateSort | 2009 |
| publisher | HERZ, Health-Economics-Research-Zentrum |
| record_format | marc |
| series | Schriften zur Gesundheitsökonomie |
| series2 | Schriften zur Gesundheitsökonomie |
| spelling | Impact of Big Pharma organizational structure on R&D productivity Sebastian Held ... Impact of Big Pharma organizational structure on Research and Development productivity Burgdorf HERZ, Health-Economics-Research-Zentrum 2009 X, 143 S. graph. Darst. txt rdacontent n rdamedia nc rdacarrier Schriften zur Gesundheitsökonomie 17 Betriebliche Forschung stw Großindustrie stw Innovation stw Organisationsstruktur stw Pharmazeutische Forschung stw Produktivität stw Welt stw Pharmazeutische Industrie (DE-588)4045696-1 gnd rswk-swf Forschung und Entwicklung (DE-588)4017897-3 gnd rswk-swf Organisation (DE-588)4043774-7 gnd rswk-swf Großbetrieb (DE-588)4022149-0 gnd rswk-swf Pharmazeutische Industrie (DE-588)4045696-1 s Großbetrieb (DE-588)4022149-0 s Organisation (DE-588)4043774-7 s Forschung und Entwicklung (DE-588)4017897-3 s DE-604 Held, Sebastian Sonstige oth Schriften zur Gesundheitsökonomie 17 (DE-604)BV017303654 17 HBZ Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=018642044&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Impact of Big Pharma organizational structure on R&D productivity Schriften zur Gesundheitsökonomie Betriebliche Forschung stw Großindustrie stw Innovation stw Organisationsstruktur stw Pharmazeutische Forschung stw Produktivität stw Welt stw Pharmazeutische Industrie (DE-588)4045696-1 gnd Forschung und Entwicklung (DE-588)4017897-3 gnd Organisation (DE-588)4043774-7 gnd Großbetrieb (DE-588)4022149-0 gnd |
| subject_GND | (DE-588)4045696-1 (DE-588)4017897-3 (DE-588)4043774-7 (DE-588)4022149-0 |
| title | Impact of Big Pharma organizational structure on R&D productivity |
| title_alt | Impact of Big Pharma organizational structure on Research and Development productivity |
| title_auth | Impact of Big Pharma organizational structure on R&D productivity |
| title_exact_search | Impact of Big Pharma organizational structure on R&D productivity |
| title_full | Impact of Big Pharma organizational structure on R&D productivity Sebastian Held ... |
| title_fullStr | Impact of Big Pharma organizational structure on R&D productivity Sebastian Held ... |
| title_full_unstemmed | Impact of Big Pharma organizational structure on R&D productivity Sebastian Held ... |
| title_short | Impact of Big Pharma organizational structure on R&D productivity |
| title_sort | impact of big pharma organizational structure on r d productivity |
| topic | Betriebliche Forschung stw Großindustrie stw Innovation stw Organisationsstruktur stw Pharmazeutische Forschung stw Produktivität stw Welt stw Pharmazeutische Industrie (DE-588)4045696-1 gnd Forschung und Entwicklung (DE-588)4017897-3 gnd Organisation (DE-588)4043774-7 gnd Großbetrieb (DE-588)4022149-0 gnd |
| topic_facet | Betriebliche Forschung Großindustrie Innovation Organisationsstruktur Pharmazeutische Forschung Produktivität Welt Pharmazeutische Industrie Forschung und Entwicklung Organisation Großbetrieb |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=018642044&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV017303654 |
| work_keys_str_mv | AT heldsebastian impactofbigpharmaorganizationalstructureonrdproductivity AT heldsebastian impactofbigpharmaorganizationalstructureonresearchanddevelopmentproductivity |